Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance

Gilead Sciences, Inc.Trade
Vanguard Total Stock Market Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $136.86 (market cap $168.35B), while Vanguard Total Stock Market Index Fund ETF trades at $381.74. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDVTI
Market Cap
$168.35B
Sector
Health
52-Week High
$155.80$381.78
52-Week Low
$110.56$311.68
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Vanguard Total Stock Market Index Fund ETF

VTI trades at $381.85, up 0.06% with a bullish technical signal from moving averages. The ETF maintains broad diversification across 3,500+ US stocks with a low 0.03% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing holdings while others reduced exposure.

The outlook remains positive given VTI's role as a core total market holding, though the elevated RSI suggests potential near-term consolidation. Key risks include market concentration in large-cap tech and broader economic volatility affecting overall equity performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Vanguard Total Stock Market Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Read more on VTI